FDA Issues Warning Letter to Bell-More Laboratories - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Issues Warning Letter to Bell-More Laboratories


ePT--the Electronic Newsletter of Pharmaceutical Technology

Untitled Document

Rockville, MD (Jan. 5)—The US Food and Drug Administration (www.fda.gov) issued a Warning Letter to Bell-More Laboratories (Hampstead, MD, www.bell-more.com) following the agency’s August 2006 inspection of the company’s Hampstead pharmaceutical facility. During the inspection, the agency documented deviations from CGMP regulations in 21 CFR Parts 210 and 211 that caused Bell-More’s finished products to be adulterated. The agency asserted that Bell-More’s inadequate controls and documentation create the potential for the migration of potent compounds throughout the facility.

The deviations enumerated in the letter include the failure to establish defined areas or other control systems to prevent contamination or mixups for handling and manufacturing potent compounds; the failure to keep records for the maintenance, cleaning, and sanitizing of equipment; the failure to adequately validate cleaning procedures for manufacturing and packaging equipment; the failure to establish and follow procedures to prevent microbiological contamination; the failure to establish procedures to ensure drug identity, strength, quality, and purity; and the failure to establish testing procedures for finished product.

Bell-More Laboratories is a contract pharmaceutical manufacturer specializing in the custom lyophilization of small-volume parenteral drugs in vials and syringes. For the full text of the Warning Letter, click here.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here